In patients with heart failure, how often was pioglitazone stopped?
The number of patients who stopped study drug treatment, for all reasons, was the same in each group. Only 34 patients (out of 149 [22.8%]) in the pioglitazone group and 17 (out of 108 [15.7%]) in the placebo group had a serious heart failure event that resulted in permanent discontinuation of the study medication. The proportion of patients with serious heart failure for whom the heart failure event resolved during follow-up was 77.9% (n=116) for pioglitazone and 74.1% (n=80) for placebo. The number of patients who died from heart failure was the same in both groups, despite heart failure being reported more often in the pioglitazone group.
Related Questions
- Should general practitioners use the electrocardiogram to select patients with suspected heart failure for echocardiography?
- What are the precautions patients with heart failure and those with stents and prosthetic valves should take?
- In patients with heart failure, how often was pioglitazone stopped?
